USA - NASDAQ:CLOV - US18914F1030 - Common Stock
The current stock price of CLOV is 2.47 USD. In the past month the price decreased by -8.86%. In the past year, price decreased by -18.75%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| UNH | UNITEDHEALTH GROUP INC | 15.32 | 291.50B | ||
| ELV | ELEVANCE HEALTH INC | 10.62 | 73.37B | ||
| HUM | HUMANA INC | 12.53 | 28.52B | ||
| CNC | CENTENE CORP | 9 | 17.87B | ||
| HQY | HEALTHEQUITY INC | 28.91 | 8.77B | ||
| MOH | MOLINA HEALTHCARE INC | 7.45 | 7.45B | ||
| ALHC | ALIGNMENT HEALTHCARE INC | N/A | 3.27B | ||
| PGNY | PROGYNY INC | 38.97 | 2.11B |
Clover Health Investments Corp. is a physician enablement technology company, which engages in the provision of Medicare Advantage plans in the United States. The company is headquartered in Jersey City, New Jersey and currently employs 570 full-time employees. The company went IPO on 2020-06-12. The firm is focused on bringing access to healthcare to everyone on Medicare. This includes a health equity-based focus on seniors, who have historically lacked access to affordable healthcare. Its software platform, Clover Assistant, is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. The Company, through its Insurance segment, provides Preferred Provider Organization (PPO) and Health Maintenance Organization (HMO) plans to Medicare Advantage (MA) members in several states, with a differentiated focus on its flagship wide-network, high-choice PPO plans. For healthcare providers outside its MA plan, it focuses on extending the benefits of its data-driven technology platform to a wider audience via its subsidiary, Counterpart Health, Inc.
CLOVER HEALTH INVESTMENTS CO
30 Montgomery Street
Jersey City NEW JERSEY 37067 US
CEO: Vivek Garipalli
Employees: 570
Phone: 12014322133
Clover Health Investments Corp. is a physician enablement technology company, which engages in the provision of Medicare Advantage plans in the United States. The company is headquartered in Jersey City, New Jersey and currently employs 570 full-time employees. The company went IPO on 2020-06-12. The firm is focused on bringing access to healthcare to everyone on Medicare. This includes a health equity-based focus on seniors, who have historically lacked access to affordable healthcare. Its software platform, Clover Assistant, is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. The Company, through its Insurance segment, provides Preferred Provider Organization (PPO) and Health Maintenance Organization (HMO) plans to Medicare Advantage (MA) members in several states, with a differentiated focus on its flagship wide-network, high-choice PPO plans. For healthcare providers outside its MA plan, it focuses on extending the benefits of its data-driven technology platform to a wider audience via its subsidiary, Counterpart Health, Inc.
The current stock price of CLOV is 2.47 USD.
CLOV does not pay a dividend.
CLOV has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
CLOV stock is listed on the Nasdaq exchange.
CLOVER HEALTH INVESTMENTS CO (CLOV) operates in the Health Care sector and the Health Care Providers & Services industry.
The outstanding short interest for CLOVER HEALTH INVESTMENTS CO (CLOV) is 13.37% of its float.
ChartMill assigns a fundamental rating of 2 / 10 to CLOV. While CLOV seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months CLOV reported a non-GAAP Earnings per Share(EPS) of -0.11. The EPS increased by 42.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -7.55% | ||
| ROE | -12.62% | ||
| Debt/Equity | 0 |
9 analysts have analysed CLOV and the average price target is 3.43 USD. This implies a price increase of 39.03% is expected in the next year compared to the current price of 2.47.
For the next year, analysts expect an EPS growth of -20.89% and a revenue growth 24.42% for CLOV